Atossa Genetics news about it getting approval from the U.S. Food and Drug Administration (FDA) for one its its drugs has its stock soaring.
Atossa Genetics News: FDA Approval Sends ATOS Stock SkyrocketingMore
Atossa Genetics (NASDAQ:ATOS) has announced that its breast cancer drug Endoxifen has been given special approval by the FDA. This approval is for using the drug to treat a specific patient under the organization’s expanded access program.
This Atossa Genetics news has the company using Endoxifen as a “post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient.” This same patient also took part in a three-week course of the drug prior to her surgery.